Navigation Links
Elsevier Delivers Unified Medication Management Platform in China

SHANGHAI, December 12, 2013 /PRNewswire/ --

Innovative clinical decision support application an example of U.K.-Sino collaboration to drive localized solutions for improved medical, health and patient care

Elsevier, a world-leading provider of scientific, technical and medical (STM) information products and services, and part of the Reed Elsevier group, announced today that it has successfully deployed the unified clinical medication decision support solution, known as Clinical Medication Decision Support All (CMDS- All), at The First Affiliated Hospital of Soochow University in Suzhou, Jiangsu province, China.

Developed by Shanghai Datong Medical Information Technology Co. Ltd. (Datong), a fully-owned Elsevier entity that focuses on delivering localized solutions for drug-related decision support, CMDS-All integrates previously disparate medical and pharmacological applications into a single solution platform with additional functionalities of prescription and analytics solutions.

"This milestone development leverages our strong U.K.-Sino relationship that pairs Elsevier's suite of quality international medical content and advanced technology with local expertise to deliver innovative customized solutions that address specific market needs," said Ron Mobed, Elsevier's Chief Executive Officer. "Elsevier's strategy of targeted investments has led to the creation of innovative products, solutions and services that serve to elevate the standard of health services for local communities."

CMDS-All is deployed as an end-user application software solution supported with a backend system that provides real-time information and alerts. These are based on analytical processing of integrated content such as patient information, patient prescription history, drug-related database and health information systems to deliver real-time medication decision support to clinicians and health care providers.

Through an integrated medication solutions platform, CMDS-All offers medical and health care institutions the advantages of:

  • Greater operational efficiencies for healthcare providers from better utilization of resources through consolidation of multiple disparate applications into a single integrated system such as basic patient information, electronic medical records, laboratory information systems and prescription histories
  • Improved and faster responsiveness through a central monitoring and alert system integrating critical medical, drug-related and patient information as well as health information systems
  • More comprehensive and greater prescription accuracy through medication analytics to avoid drug-related errors and malpractices
  • Improved and better hospital and patient management through real-time monitoring and drug administration resulting in better health and patient care

"Continuous reforms in China's health care sector are requiring medical and health organizations to provide safer, faster and more efficient medical services with greater accuracy for better patient care, and CMDS-All is the one-stop clinical medication decision support system that addresses those needs," said Yukun Harsono, Managing Director of Elsevier for Greater China. "CMDS-All is the enabling solution that is able to deliver the right information to clinical practitioners at the right time to make the right decision for the best outcomes."

# # #

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Jason Chan
Director, Corporate Relations, Asia Pacific

SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
4. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
7. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
8. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
9. Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type
10. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
11. Elsevier Launches New Journal: Learning, Culture and Social Interaction
Post Your Comments:
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
Breaking Biology Technology:
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):